The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha-chain of the complement component, C3
- PMID: 2473125
The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha-chain of the complement component, C3
Erratum in
- J Immunol 1989 Dec 1;143(11):3860-1
Abstract
The third component of the human C system, C3, exhibits two common genetic variants. These variants have been characterized by high voltage agarose electrophoresis and are designated C3 fast (C3F) and C3 slow (C3S). C3F occurs at appreciable frequencies only in Caucasian populations and has been shown to be associated with an increased incidence of certain diseases, such as partial lipodystrophy, IgA nephropathy, and Indian childhood cirrhosis. It has been shown that C3F differs from C3S with regard to isoelectric point as well as its ability to bind macrophages. The availability of a full-length cDNA probe for human C3 has made it possible to study the polymorphism at the genomic level. We have used RNA/RNA hybridization to demonstrate that the difference between C3F and C3S occurs in the C3d region. We subsequently used oligonucleotide-primed DNA amplification to show that C3F arises from a point mutation at codon 1216 converting a deoxyadenosine for a deoxyguanosine. The result of this point mutation at the translational level is the substitution of an asparagine residue in C3S for an aspartic acid residue in C3F. It is known that C3d contains the binding site for CR2 as well as the internal thioester site and multiple protease cleavage sites. The identification of the structural basis of the differences between C3F and C3S will assist our continuing studies of the mechanism of the functional differences between the two alleles and the disease associations of C3F. It also allows us to use DNA based techniques to allotype C3 in subjects with little or no C3 in their serum.
Similar articles
-
The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha chain of the complement component, C3.J Immunol. 1989 Dec 1;143(11):3860-2. J Immunol. 1989. PMID: 2584723 No abstract available.
-
Molecular analysis of C3 allotypes in patients with systemic vasculitis.Nephrol Dial Transplant. 1994;9(11):1564-7. Nephrol Dial Transplant. 1994. PMID: 7870343
-
Molecular analysis of C3 allotypes related to transplant outcome in human renal allografts.Transplantation. 1995 Dec 15;60(11):1342-6. Transplantation. 1995. PMID: 8525532
-
Complement C3 and its polymorphism: biological and clinical consequences.Pathology. 2014 Jan;46(1):1-10. doi: 10.1097/PAT.0000000000000042. Pathology. 2014. PMID: 24300728 Review.
-
[Characteristics of polymorphic variants of the 3d component od the complement system. Association of C3F with various diseases].Pol Arch Med Wewn. 1988 Jul;80(1):28-35. Pol Arch Med Wewn. 1988. PMID: 3078202 Review. Polish. No abstract available.
Cited by
-
New approaches to the treatment of dense deposit disease.J Am Soc Nephrol. 2007 Sep;18(9):2447-56. doi: 10.1681/ASN.2007030356. Epub 2007 Aug 5. J Am Soc Nephrol. 2007. PMID: 17675665 Free PMC article. Review.
-
Polymorphisms in complement component 3 (C3F) and complement factor H (Y402H) increase the risk of postoperative neurocognitive dysfunction following carotid endarterectomy.J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):247-53. doi: 10.1136/jnnp.2010.211144. Epub 2010 Sep 14. J Neurol Neurosurg Psychiatry. 2011. PMID: 20841369 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Miscellaneous